A double-edged sword in B-cell-targeted therapy for inflammatory diseases

Area of Science:

• Immunology
• Cell Biology
• Therapeutics

Background:

• B cells play dual roles in immunity, mediating inflammation against pathogens and initiating anti-inflammatory responses to prevent host damage.
• B-cell-depletion therapy using anti-CD20 monoclonal antibodies shows variable efficacy in inflammatory diseases, dependent on treatment timing and microenvironment.
• Understanding the diverse functions of B cells, including antibody production, cytokine release, and antigen presentation, is crucial for targeted therapeutic strategies.

Purpose of the Study:

• To elucidate the multifaceted roles of pathogenic and regulatory B cells in immune responses.
• To identify key B cell functions and interactions critical for developing effective B cell-targeted therapies.
• To explore strategies for precise B cell subset targeting to optimize therapeutic outcomes and reduce host damage.

Main Methods:

• Review and analysis of existing literature on B cell immunobiology and therapeutic interventions.
• Examination of B cell functions such as antibody production, cytokine secretion, antigen presentation, and interactions with other immune cells.
• Investigation of the impact of B cell-depletion therapy on inflammatory and anti-inflammatory processes.

Main Results:

• B cells exhibit a complex range of functions, including antibody production, immune complex formation, cytokine/chemokine release, cytotoxic activity, lymphoid neogenesis, and antigen presentation.
• B cells interact extensively with dendritic cells, T cells, and natural killer T cells, forming intricate regulatory networks.
• The therapeutic effects of anti-CD20 therapies are contingent upon the specific B cell subsets targeted and the surrounding microenvironmental context.

Conclusions:

• Effective B cell-targeted therapy necessitates a comprehensive understanding of the distinct roles of various B cell subsets.
• Precise targeting of specific B cell populations or their interaction partners holds promise for enhancing clinical benefits in inflammatory diseases.
• Minimizing host damage requires careful consideration of the timing and microenvironment during B cell-directed therapeutic interventions.